Pharma faces 30-day deadline under Trump’s pricing order
US President Donald Trump has signed an executive order aimed at reducing prescription drug prices by linking them to what …
Post
-
-
Rein Therapeutics begins trial for idiopathic pulmonary fibrosis treatment
Rein Therapeutics has initiated the randomised RENEW Phase II trial of its Caveolin-1-related peptide, LTI-03, targeting idiopathic pulmonary fibrosis (IPF), …
-
Republicans’ proposed Medicaid cuts met with dismay
The Trump Administration in the US has introduced legislation outlining plans for deep cuts and limitations to Medicaid, which observers …
-
GLP-1RAs show anti-cancer benefits beyond weight loss
A study has found that glucagon-like peptide-1 receptor agonists (GLP-1RAs) offer anti-cancer benefits that extend beyond their role in promoting …
-
HIV market expected to reach $32.1bn by 2033 in 7MM
The human immunodeficiency virus (HIV) market across the seven major markets (7MM), comprising the US, France, Germany, Italy, Spain, the …
-
GLP-1RAs show anti-cancer benefits beyond weight loss
A study has found that glucagon-like peptide-1 receptor agonists (GLP-1RAs) offer anti-cancer benefits that extend beyond their role in promoting …
-
HIV market expected to reach $32.1bn by 2033 in 7MM
The human immunodeficiency virus (HIV) market across the seven major markets (7MM), comprising the US, France, Germany, Italy, Spain, the …
-
EMA approves Moleculin’s application for Phase IIb/III AML trial
The European Medicines Agency (EMA) has approved Moleculin Biotech’s clinical trial application (CTA) for a pivotal, multi-centre Phase IIb/III trial …
-
Can PD-1 checkpoint inhibition enhance the NMIBC standard of care?
Bladder cancer accounts for over 200,000 deaths every year globally, with non-muscle invasive bladder cancer (NMIBC) making up 75% of …
-
Novo Nordisk’s Sogroya matches Norditropin in children’s growth disorders
Novo Nordisk’s once-weekly Sogroya (somapacitan) has proved to be non-inferior to the once-daily growth hormone Norditropin (somatropin) in children’s growth …
-
US-China tariffs pause ‘positive’ but uncertainty remains – analyst
The deal between the US and China to reduce for 90 days the tariffs recently imposed on imports of each …
-
LEO Pharma reports outcomes from Phase IIb trial of atopic dermatitis therapy
LEO Pharma has reported positive topline outcomes from the randomised Phase IIb trial of the IL-22 receptor subunit alpha 1 …
-
Trump to sign order tying US drug prices to global rates
In a renewed push to overhaul pharmaceutical pricing in the US, President Donald Trump announced he will sign an executive …
-
Vir’s hepatitis B combo falls short in Phase II trial
Vir Biotechnology’s ‘functional cure’ combination therapy has failed to meet the efficacy endpoints in a Phase II trial in hepatitis …
-
AstraZeneca’s Imfinzi combo shows DFS improvement in bladder cancer trial
AstraZeneca's human monoclonal antibody Imfinzi (durvalumab), when combined with standard-of-care Bacillus Calmette-Guérin (BCG) induction and maintenance therapy, showed disease-free survival …
